Aucta has several ongoing development projects for the treatment of people with seizure disorders.

Epilepsy is a central nervous system (neurological) disorder in which brain activity becomes abnormal, causing seizures or periods of unusual behavior, sensations, and sometimes loss of awareness.

Approximately 50 million people currently live with epilepsy worldwide.  Globally, an estimated 2.4 million people are diagnosed with epilepsy each year. In high-income countries, annual new cases are between 30 and 50 per 100,000 people in the general population. In low- and middle-income countries, this figure can be up to 2 times higher.

Epilepsy and seizure-related disorders affect nearly 3 million people in the United States annually, at an estimated annual cost of $17.6 billion in direct and indirect costs. Two hundred thousand new cases of seizures are reported annually in the US, and approximately 10% of the American population will experience at least one seizure in their lifetime. Seizures dramatically affect quality of life and activities of daily living.  China has 6 million to 7 million people affected by epilepsy; incidence in children and elder adults (>65 years of age) are much higher, and pediatric epilepsy prevalence is estimated at 2.98 to 8.8%, or about 10x to 15x that of adults.

Currently available anti-epileptic drugs (AEDs) are used to treat various seizure types and patient populations. However, there is a clear need for age-appropriate dosage forms to treat people living with epilepsy as well as to improve the titration and dosing challenges associated with many of these drugs. 

In addition, for many of the CNS conditions, including bipolar disorder, schizophrenia, and epilepsy, more patient-friendly dosage forms such as extended-release formulations that enable once-daily dosing are needed.